Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial.
暂无分享,去创建一个
Lawrence A Leiter | B. Lewis | A. Keech | R. Giugliano | M. Sabatine | S. Murphy | P. Sever | P. Deedwania | S. Wiviott | Y. Handelsman | I. Gouni-Berthold | T. Pedersen | N. Honarpour | J. Kuder | A. Pineda | G. D. de Ferrari | Armando Lira Pineda | Narimon Honarpour